Navigation Links
Essilor - 2009 Financial Results
Date:3/4/2010

United States, India and South Africa, along with a distributor in Brazil, for total additional full-year revenue of EUR23 million.

                    CONTRIBUTION MARGIN AT 18.2%

    EUR millions                           2009       2008

    Gross margin                        1,832.6    1,749.3

    As a % of revenue                      56.1       56.9
    Operating expenses                  1,238.2    1,198.2
    Contribution from operations(1)       594.4      551.2

    As a % of revenue                      18.2       17.9

    (1) Operating profit before compensation costs of share-based
        payments, restructuring costs, other income and expense, and
        goodwill impairment.

The contribution from operations increased 7.9% to EUR594.4 million in 2009, while the contribution margin improved by 0.3 points to 18.2%, despite the dilutive impact of consolidating Satisloh. The growth may be analyzed as follows:

    - Gross margin declined by 0.8 points to 56.1% of revenue, due to the
      dilutive impact from Satisloh and other acquisitions. Excluding the
      impact of these acquisitions, gross margin was unchanged for the year.
    - Operating expenses as a percentage of revenue declined by 1.1 point,
      to 37.9%, thanks to i) tight control over selling and distribution
      costs (EUR706.6 million) and major reductions in overheads while
      maintaining a strong research and development commitment (funded at
      EUR151.2 million before deduction of a EUR10.4 million research tax
      credit) and ii) the positive impact of acquisitions who
'/>"/>
SOURCE Essilor
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine news :

1. Essilor : First Half 2009 Results
2. Essilor : 2008 Results
3. Essilor : 2008 Revenue
4. Essilor Agrees to Acquire Signet Armorlite
5. Essilor Steps Up its Development in Eastern Europe
6. Essilor - First-Half 2008 Revenue
7. Essilor Agrees to Acquire Satisloh The World Leader in Optical Manufacturing Solutions
8. Essilors 2008 First-Quarter Report
9. Essilor Strengthens its Positions in Italy - Three New Acquisitions in the United States
10. Essilor : 2007 Results
11. Essilor Enters Bulgarian Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... MD (April 23, 2014) The American Gastroenterological ... the 2014 AGA Research Scholars. The AGA Research ... investigators to develop independent and productive research careers ... Scholar Awards fund an additional year allowing for ... committed to supporting junior faculty who are paving ...
(Date:4/23/2014)... scientists led by a researcher from the Cancer Science ... of Singapore has identified the cancer specific stem cell ... possibility of developing new drugs for the treatment of ... research group, led by Dr Chan Shing Leng, Research ... time that a cancer-specific variant of a cell surface ...
(Date:4/23/2014)... have shown that proliferation of endogenous neural precursor ... neurons and axons. From the perspective of neural ... Yat-sen University in China observed the effects of ... cell proliferation and expression of basic fibroblast growth ... brain on the infarct side. The researchers found ...
(Date:4/22/2014)... few decades researchers have characterized a set of clock ... in all types of species, from flies to humans. ... researchers surmise there are more. A team from the ... wondered if big-data approaches could find them. , ... Hogenesch, PhD, professor of Pharmacology and first author Ron ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... March 18 German medical device,manufacturer Ziehm Imaging ... European Congress of Radiology (ECR) in Vienna. This ... requiring minimal OR space. The,system provides flexible image ... OR monitors. Ziehm Solo was designed to meet ...
... provider of comprehensive medical record solutions for healthcare ... on Wednesday, March 25th at their headquarters in ... Future" will focus on the rollout of the ... meant to promote the integration of electronic medical ...
... 17 The Generic Pharmaceutical Association (GPhA) released the ... Jaeger regarding the introduction of H.R. 1548, "The Pathway ... is the wrong road for patients looking for safe ... times. It is a long route filled with ...
... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, ... Senior Vice President of Government Affairs on the ... Eshoo and Joe Barton: "In this year of ... to affordable medicines. The legislation re-introduced in the ...
... University of Illinois at Chicago College of Medicine have ... protein snarls found in the brains of Alzheimer,s patients ... needed to combat the neurodegenerative disease. , Alzheimer,s disease, ... and is among the most costly diseases to society ...
... WASHINGTON, March 17 A federal jury in Miami ... connection with a $5.3 million Medicare fraud scheme, Acting ... Division and U.S. Attorney R. Alexander Acosta of the ... federal court in Miami, a jury found David Rothman, ...
Cached Medicine News:Health News:Ziehm Imaging Introduces Ziehm Solo C-arm, Featuring a Versatile set-up in the OR and Exceptional Image Quality 2Health News:Ziehm Imaging Introduces Ziehm Solo C-arm, Featuring a Versatile set-up in the OR and Exceptional Image Quality 3Health News:Microwize to Hold Free Stimulus Package Workshop for Medical Industry 2Health News:Microwize to Hold Free Stimulus Package Workshop for Medical Industry 3Health News:GPhA Statement on Introduction of H.R. 1548, 'The Pathway for Biosimilars Act' 2Health News:Mechanism of Alzheimer's suggests combination therapy needed 2Health News:Mechanism of Alzheimer's suggests combination therapy needed 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 2Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 3Health News:Jury Convicts Two Doctors and Two Medical Assistants in $5.3 Million Medicare Fraud Scam 4
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18